Pfizer Inc. (NYSE:PFE) Shares Acquired by Excalibur Management Corp

Excalibur Management Corp increased its position in shares of Pfizer Inc. (NYSE:PFE) by 1.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 164,336 shares of the biopharmaceutical company’s stock after acquiring an additional 3,090 shares during the quarter. Pfizer makes up approximately 1.9% of Excalibur Management Corp’s holdings, making the stock its 9th biggest holding. Excalibur Management Corp’s holdings in Pfizer were worth $4,598,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Olistico Wealth LLC acquired a new position in Pfizer in the second quarter valued at $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at about $29,000. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the 4th quarter worth about $32,000. Trivant Custom Portfolio Group LLC increased its position in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. purchased a new stake in Pfizer during the 2nd quarter worth $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 2.7 %

Shares of Pfizer stock opened at $30.07 on Tuesday. The stock has a 50 day moving average price of $29.26 and a two-hundred day moving average price of $28.15. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $34.12. The stock has a market capitalization of $170.40 billion, a P/E ratio of -501.08, a PEG ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the previous year, the firm posted $0.67 EPS. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.59%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer’s dividend payout ratio is presently -2,799.53%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. UBS Group raised their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday. Barclays raised their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.